Ontology type: schema:ScholarlyArticle Open Access: True
2017-11-02
AUTHORSMichael Wang, Stephen J. Schuster, Tycel Phillips, Izidore S. Lossos, Andre Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B. Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo, Peter Martin
ABSTRACTBackgroundThe observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance.MethodsThe primary endpoint was investigator-assessed overall response rate based on the 2007 International Working Group criteria.ResultsOf 58 enrolled patients (median age, 71 years; range, 50–89), 13 received lenalidomide monotherapy, 11 lenalidomide plus rituximab, and 34 lenalidomide plus other treatment. Most patients (88%) had received ≥ 3 prior therapies (median 4; range, 1–13). Median time from last dose of ibrutinib to the start of lenalidomide was 1.3 weeks (range, 0.1–21.7); 45% of patients had partial responses or better to prior ibrutinib. Primary reasons for ibrutinib discontinuation were lack of efficacy (88%) and ibrutinib toxicity (9%). After a median of two cycles (range, 0–11) of lenalidomide-based treatment, 17 patients responded (8 complete responses, 9 partial responses), for a 29% overall response rate (95% confidence interval, 18–43%) and a median duration of response of 20 weeks (95% confidence interval, 2.9 to not available). Overall response rate to lenalidomide-based therapy was similar for patients with relapsed/progressive disease after previous response to ibrutinib (i.e., ≥PR) versus ibrutinib-refractory (i.e., ≤SD) patients (30 versus 32%, respectively). The most common all-grade treatment-emergent adverse events after lenalidomide-containing therapy (n = 58) were fatigue (38%) and cough, dizziness, dyspnea, nausea, and peripheral edema (19% each). At data cutoff, 28 patients have died, primarily due to mantle cell lymphoma.ConclusionLenalidomide-based treatment showed clinical activity, with no unexpected toxicities, in patients with relapsed/refractory mantle cell lymphoma who previously failed ibrutinib therapy.Trial registrationClinicaltrials.gov identifier NCT02341781. Date of registration: January 14, 2015 More... »
PAGES171
http://scigraph.springernature.com/pub.10.1186/s13045-017-0537-5
DOIhttp://dx.doi.org/10.1186/s13045-017-0537-5
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1092508548
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/29096668
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adenine",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease Progression",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lenalidomide",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lymphoma, Mantle-Cell",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Piperidines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pyrazoles",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pyrimidines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Recurrence",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Thalidomide",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA",
"id": "http://www.grid.ac/institutes/grid.240145.6",
"name": [
"Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "Wang",
"givenName": "Michael",
"id": "sg:person.01170433215.91",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170433215.91"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA",
"id": "http://www.grid.ac/institutes/grid.25879.31",
"name": [
"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA"
],
"type": "Organization"
},
"familyName": "Schuster",
"givenName": "Stephen J.",
"id": "sg:person.011060364477.44",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011060364477.44"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Michigan, Ann Arbor, MI, USA",
"id": "http://www.grid.ac/institutes/grid.214458.e",
"name": [
"University of Michigan, Ann Arbor, MI, USA"
],
"type": "Organization"
},
"familyName": "Phillips",
"givenName": "Tycel",
"id": "sg:person.013116564627.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013116564627.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sylvester Comprehensive Cancer Center, Division of Hematology Oncology, University of Miami, Miami, FL, USA",
"id": "http://www.grid.ac/institutes/grid.419791.3",
"name": [
"Sylvester Comprehensive Cancer Center, Division of Hematology Oncology, University of Miami, Miami, FL, USA"
],
"type": "Organization"
},
"familyName": "Lossos",
"givenName": "Izidore S.",
"id": "sg:person.01156610632.10",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156610632.10"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "John Theurer Cancer Center at HUMC, Hackensack, NJ, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"John Theurer Cancer Center at HUMC, Hackensack, NJ, USA"
],
"type": "Organization"
},
"familyName": "Goy",
"givenName": "Andre",
"id": "sg:person.01241267414.41",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241267414.41"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Haematology, Derriford Hospital and Plymouth University Medical School, Plymouth, UK",
"id": "http://www.grid.ac/institutes/grid.11201.33",
"name": [
"Department of Haematology, Derriford Hospital and Plymouth University Medical School, Plymouth, UK"
],
"type": "Organization"
},
"familyName": "Rule",
"givenName": "Simon",
"id": "sg:person.01234451652.30",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234451652.30"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medical College of Wisconsin & CIBMTR, Milwaukee, WI, USA",
"id": "http://www.grid.ac/institutes/grid.30760.32",
"name": [
"Medical College of Wisconsin & CIBMTR, Milwaukee, WI, USA"
],
"type": "Organization"
},
"familyName": "Hamadani",
"givenName": "Mehdi",
"id": "sg:person.01333152475.54",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333152475.54"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Carolinas HealthCare System, Levine Cancer Institute, Charlotte, NC, USA",
"id": "http://www.grid.ac/institutes/grid.468189.a",
"name": [
"Carolinas HealthCare System, Levine Cancer Institute, Charlotte, NC, USA"
],
"type": "Organization"
},
"familyName": "Ghosh",
"givenName": "Nilanjan",
"id": "sg:person.01313727374.95",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01313727374.95"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Mayo Clinic Scottsdale/Phoenix, Scottsdale, AZ, USA",
"id": "http://www.grid.ac/institutes/grid.417468.8",
"name": [
"Mayo Clinic Scottsdale/Phoenix, Scottsdale, AZ, USA"
],
"type": "Organization"
},
"familyName": "Reeder",
"givenName": "Craig B.",
"id": "sg:person.01016243767.04",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016243767.04"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Celgene Corporation, Summit, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.419971.3",
"name": [
"Celgene Corporation, Summit, NJ, USA"
],
"type": "Organization"
},
"familyName": "Barnett",
"givenName": "Evelyn",
"id": "sg:person.016614405231.51",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016614405231.51"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Celgene International S\u00e0rl, Boudry, Switzerland",
"id": "http://www.grid.ac/institutes/grid.488233.6",
"name": [
"Celgene International S\u00e0rl, Boudry, Switzerland"
],
"type": "Organization"
},
"familyName": "Bravo",
"givenName": "Marie-Laure Casadebaig",
"id": "sg:person.01222210757.89",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222210757.89"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Weill Cornell Medical College, New York, NY, USA",
"id": "http://www.grid.ac/institutes/grid.5386.8",
"name": [
"Weill Cornell Medical College, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Martin",
"givenName": "Peter",
"id": "sg:person.012435725407.16",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012435725407.16"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1186/s13045-016-0313-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007668341",
"https://doi.org/10.1186/s13045-016-0313-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s13045-016-0250-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000012078",
"https://doi.org/10.1186/s13045-016-0250-9"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s40364-016-0060-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1029579455",
"https://doi.org/10.1186/s40364-016-0060-9"
],
"type": "CreativeWork"
}
],
"datePublished": "2017-11-02",
"datePublishedReg": "2017-11-02",
"description": "BackgroundThe observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance.MethodsThe primary endpoint was investigator-assessed overall response rate based on the 2007 International Working Group criteria.ResultsOf 58 enrolled patients (median age, 71\u00a0years; range, 50\u201389), 13 received lenalidomide monotherapy, 11 lenalidomide plus rituximab, and 34 lenalidomide plus other treatment. Most patients (88%) had received \u2265\u20093 prior therapies (median 4; range, 1\u201313). Median time from last dose of ibrutinib to the start of lenalidomide was 1.3\u00a0weeks (range, 0.1\u201321.7); 45% of patients had partial responses or better to prior ibrutinib. Primary reasons for ibrutinib discontinuation were lack of efficacy (88%) and ibrutinib toxicity (9%). After a median of two cycles (range, 0\u201311) of lenalidomide-based treatment, 17 patients responded (8 complete responses, 9 partial responses), for a 29% overall response rate (95% confidence interval, 18\u201343%) and a median duration of response of 20\u00a0weeks (95% confidence interval, 2.9 to\u00a0not available). Overall response rate to lenalidomide-based therapy was similar for patients with relapsed/progressive disease after previous response to ibrutinib (i.e., \u2265PR) versus ibrutinib-refractory (i.e., \u2264SD) patients (30 versus 32%, respectively). The most common all-grade treatment-emergent adverse events after lenalidomide-containing therapy (n\u00a0=\u00a058) were fatigue (38%) and cough, dizziness, dyspnea, nausea, and peripheral edema (19% each). At data cutoff, 28 patients have died, primarily due to mantle cell lymphoma.ConclusionLenalidomide-based treatment showed clinical activity, with no unexpected toxicities, in patients with relapsed/refractory mantle cell lymphoma who previously failed ibrutinib therapy.Trial registrationClinicaltrials.gov identifier NCT02341781. Date of registration: January 14, 2015",
"genre": "article",
"id": "sg:pub.10.1186/s13045-017-0537-5",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1039771",
"issn": [
"1756-8722"
],
"name": "Journal of Hematology & Oncology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "10"
}
],
"keywords": [
"overall response rate",
"refractory mantle cell lymphoma",
"mantle cell lymphoma",
"lenalidomide-based therapy",
"cell lymphoma",
"response rate",
"investigator-assessed overall response rate",
"grade treatment-emergent adverse events",
"treatment-emergent adverse events",
"International Working Group criteria",
"MethodsThe primary endpoint",
"lack of efficacy",
"lenalidomide monotherapy",
"prior therapy",
"ibrutinib discontinuation",
"ibrutinib toxicity",
"primary endpoint",
"last dose",
"peripheral edema",
"data cutoff",
"ibrutinib therapy",
"most patients",
"partial response",
"median duration",
"progressive disease",
"adverse events",
"median time",
"Group criteria",
"ibrutinib failure",
"clinical activity",
"observational study",
"unexpected toxicities",
"patients",
"lenalidomide",
"lymphoma",
"therapy",
"ibrutinib",
"treatment",
"weeks",
"previous response",
"toxicity",
"dyspnea",
"monotherapy",
"rituximab",
"nausea",
"discontinuation",
"cough",
"dizziness",
"response",
"edema",
"primary reason",
"intolerance",
"disease",
"dose",
"endpoint",
"median",
"efficacy",
"outcomes",
"rate",
"study",
"duration",
"failure",
"fatigue",
"cutoff",
"criteria",
"activity",
"start",
"lack",
"events",
"reasons",
"time",
"cycle"
],
"name": "Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)",
"pagination": "171",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1092508548"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s13045-017-0537-5"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"29096668"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s13045-017-0537-5",
"https://app.dimensions.ai/details/publication/pub.1092508548"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:33",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_735.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s13045-017-0537-5"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13045-017-0537-5'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13045-017-0537-5'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13045-017-0537-5'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13045-017-0537-5'
This table displays all metadata directly associated to this object as RDF triples.
315 TRIPLES
22 PREDICATES
116 URIs
105 LITERALS
22 BLANK NODES